Oramed Pharmaceuticals INC.: directors' dealings · United States · SEC (Form 4)

About Oramed Pharmaceuticals INC.

Oramed Pharmaceuticals Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ market (ticker: ORMP), with regulatory references that also reflect its historical international footprint. The company is headquartered in New York, United States, and was established in 2006. Its business model is built around a proprietary oral drug-delivery platform designed to convert therapies that are typically administered by injection into orally deliverable formulations. As a result, Oramed is best viewed as a platform-driven specialty biotech rather than a traditional commercial pharma company. The company’s core strategic asset is its oral insulin program, developed around its Protein Oral Delivery (POD™) technology. This platform is intended to protect sensitive therapeutic proteins in the digestive tract and enhance absorption so they can be taken by mouth. Oramed’s flagship product candidate, ORMD-0801, has been positioned as an oral insulin capsule for diabetes, especially type 2 diabetes, and has been studied in clinical trials, including trials run in the United States under FDA oversight. Beyond oral insulin, the company has historically explored adjacent applications of the same delivery technology and other pipeline concepts that could broaden the platform’s commercial value. From a competitive standpoint, Oramed occupies a highly specialized niche. It is not competing with large pharmaceutical companies on scale or marketed product breadth; rather, it seeks to differentiate itself through a potentially disruptive administration route. If successful, oral delivery of insulin could improve convenience, patient adherence, and early treatment acceptance versus injections. However, the company also faces the standard biotech risks: clinical uncertainty, regulatory hurdles, manufacturing complexity, and the challenge of translating proof-of-concept into a scalable commercial product. Recent developments suggest that Oramed has also been managing its balance sheet and strategic optionality actively. In 2025 and early 2026, the company announced transactions and agreements involving Scilex and Lifeward, alongside material cash proceeds from strategic investments. These events strengthened financial flexibility and are among the most important recent corporate milestones. For investors, Oramed should therefore be analyzed as a small-cap healthcare name with meaningful upside optionality, but also a high degree of execution risk tied to clinical progress, partnership strategy, and monetization of its oral-delivery intellectual property.